These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22202080)

  • 21. A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.
    Kuruvilla J; Tzeng CH; Cho SG; Kim SJ; Tang JL; Su Y; Wu J; Vargo R; Cheverton P
    Bone Marrow Transplant; 2019 Feb; 54(2):258-264. PubMed ID: 29895931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
    Jantunen E; Varmavuo V; Valtola J
    Expert Rev Hematol; 2016 Aug; 9(8):723-32. PubMed ID: 27355397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation.
    Flomenberg N; Comenzo RL; Badel K; Calandra G
    Biol Blood Marrow Transplant; 2010 May; 16(5):695-700. PubMed ID: 20067838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.
    Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN
    Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.
    Karres D; Ali S; van Hennik PB; Straus S; Josephson F; Thole G; Glerum PJ; Herberts C; Babae N; Herold R; Papadouli I; Pignatti F
    Oncologist; 2020 Jun; 25(6):e976-e981. PubMed ID: 32154610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
    Hübel K; Fresen MM; Apperley JF; Basak GW; Douglas KW; Gabriel IH; Geraldes C; Jaksic O; Koristek Z; Kröger N; Lanza F; Lemoli RM; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
    Bone Marrow Transplant; 2012 Aug; 47(8):1046-50. PubMed ID: 22080971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plerixafor dosing and administration in a patient with dialysis-dependent renal failure.
    Gregory KM; Rao KV; Armistead PM
    Ann Pharmacother; 2010 Dec; 44(12):2028-30. PubMed ID: 21098756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
    Uy GL; Rettig MP; Cashen AF
    Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
    Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
    Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection.
    Dietz L; Marini J; Hashmi H; McGann M
    J Oncol Pharm Pract; 2024 Sep; 30(6):1073-1077. PubMed ID: 38629183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
    Smith VR; Popat U; Ciurea S; Nieto Y; Anderlini P; Rondon G; Alousi A; Qazilbash M; Kebriaei P; Khouri I; de Lima M; Champlin R; Hosing C
    Am J Hematol; 2013 Sep; 88(9):754-7. PubMed ID: 23749720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study.
    Zhu J; Huang H; Chen H; Zhang X; Li Z; Wu D; Zhou D; Song Y; Hu Y; Liang Y; Ren H; Huang H; Li N; Chen H; Hu J; Li J; Meng R; Wu J; Yu D; Huang X
    Transfusion; 2018 Jan; 58(1):81-87. PubMed ID: 29238988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
    Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
    Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
    Farina L; Spina F; Guidetti A; Longoni P; Ravagnani F; Dodero A; Montefusco V; Carlo-Stella C; Corradini P
    Leuk Lymphoma; 2014 Feb; 55(2):331-6. PubMed ID: 23656194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer.
    Saure C; Weigelt C; Schroeder T; Klärner V; Galonska L; Haas R; Kobbe G
    Acta Haematol; 2010; 124(4):235-8. PubMed ID: 21099212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Wagstaff AJ
    Drugs; 2009; 69(3):319-26. PubMed ID: 19275275
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.
    Basak GW; Jaksic O; Koristek Z; Mikala G; Basic-Kinda S; Mayer J; Masszi T; Giebel S; Labar B; Wiktor-Jedrzejczak W;
    Eur J Haematol; 2011 Jun; 86(6):488-95. PubMed ID: 21410533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
    Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.